Since the implementation of the national cancer strategy commenced in 1997, there has been a cumulative additional investment of approximately €400 million in the development of appropriate treatment and care services for people with cancer. This includes the sum of €29 million which was provided this year to ensure that we continue to address increasing demands in cancer services in such areas as oncology-haematology services, oncology drug treatments and symptomatic breast disease services.
Cancer services throughout the country have benefited from this investment which far exceeds the £25 million requirement which was initially envisaged under the national cancer strategy. This investment has enabled the funding of 80 additional consultant posts, together with support staff in key areas such as medical oncology, radiology, palliative care, histopathology and haematology. The benefit of this investment is reflected in the significant increase in activity which has occurred. For example, the number of new patients receiving radiotherapy treatment has increased from 2,402 in 1994 to 3,809 in 2000. This means that an additional 1,407 patients are accessing these services, representing an increase of 58% nationally. The number of new patients receiving chemotherapy treatment has increased from 2,693 in 1994 to 3,519 in 2000, representing an increase of 30% nationally. Similarly, breast cancer surgery has increased from 1,333 in 1997 to 1,854 in 2001. This is an increase of 39% nationally.
My Department has consulted with all regional health boards and the position is that oncology patients are treated as an urgent priority and are generally operated on within two weeks. I have been informed by the ERHA that there were problems earlier in the year in the Mater Hospital with regard to the cancellation of elective admissions due to the pressure on acute beds as a result of emergency admissions and delayed discharges. These problems directly affected the availability of urology beds in the Mater Hospital for elective admissions, including cancer patients. The ERHA has confirmed that the ward in question has now reverted to use for elective patients.
It is unacceptable that surgery for cancer patients should be delayed in this manner. Given the importance attached to this matter, the Eastern Regional Health Authority raised it yesterday with the chief executive officers of the Dublin academic teaching hospitals, including the Mater Hospital. At this meeting, the chief executive officer of the hospital concerned assured the ERHA that priority admissions such as urgent cancer cases are protected as far as possible.
Additional information
I emphasise that the position is that cancer cases are protected and this is a major priority within acute hospitals throughout the country. My commitment to cancer services is reflected in the substantial additional investment in cancer services in recent years.